CureVac Secures Critical Second Patent Win vs BioNTech - July Court Showdown Set for mRNA Rights

CureVac (NASDAQ:CVAC) has secured another favorable ruling from the European Patent Office (EPO) in its ongoing patent litigation against BioNTech SE.